Testosterone replacement therapy for late-onset hypogonadism (Q36475967)

14 August 2017

1 reference

title

Testosterone replacement therapy for late-onset hypogonadism (English)

1 reference

14 August 2017

1 reference

1 reference

1 reference

Glenn R Cunningham

1

1 reference

PubMed ID

16691239

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

14 August 2017

Nature Reviews Urology

1 reference

14 August 2017

3

1 reference

14 August 2017

5

1 reference

14 August 2017

260-267

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro0479

14 August 2017

0 references

cites work

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

Andropause: is androgen replacement therapy indicated for the aging male?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Testosterone replacement therapy: current trends and future directions

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Andropause: invention, prevention, rejuvenation

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

The decline of androgen levels in elderly men and its clinical and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Estrogen plus progestin and the risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Serum testosterone assays--accuracy matters

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Treatment of male hypogonadism with testosterone enanthate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Hypogonadism in elderly men--what to do until the evidence comes

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

A systematic review and meta-analysis of familial prostate cancer risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Risks of testosterone-replacement therapy and recommendations for monitoring

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0479

7 January 2021

Identifiers

DOI

10.1038/NCPURO0479

1 reference

14 August 2017

1 reference

PubMed ID

16691239